Recent Advances in Diagnosis and Treatment of Pancreatic Cancer
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Molecular Cancer Biology".
Deadline for manuscript submissions: closed (30 September 2023) | Viewed by 9453
Special Issue Editor
Interests: pancreatic and periampullary cancer; pancreas transplant; pancreaticoduodenectomy; minimally invasive surgery; robotic surgery; prognosis; biomarker
Special Issue Information
Dear Colleagues,
Pancreatic cancer is a malignancy with a dismal outcome, mainly due to its aggressive biology. Surgical resection remains the only hope of cure in patients with this type of cancer. Nevertheless, the diagnosis and treatment of this notorious disease have been challenging because the pancreas is located in the deeply seated retroperitoneal space and associated with a complex anatomy. Therefore, pancreatic cancer is often diagnosed late. Moreover, resection with pancreaticoduodenectomy requires a high level of technical skill, is time-consuming, and is traditionally performed via an open approach requiring a long abdominal incision which causes severe pain and even torture for patients. Recent technological advances have made significant progress in the diagnosis and treatment of the pancreatic cancer. In diagnosis, the advances include the wide application of endoscopic ultrasound, liquid biopsy with circulating biomarkers, and precise imaging modalities. Recently, the introduction of robotic surgical systems such as the da Vinci Robotic Surgical System (Intuitive Surgical, Inc., Sunnyvale, CA, USA) has overcome several limitations related to the laparoscopic approach and driven pancreatic surgeons on the path of minimally invasive surgery. Providing a high-quality 3-D and magnified vision of the robotic scope, articulated instruments with 540 degrees of motion, greater precision with suture targeting, and elimination of surgeon tremor, the robotic approach makes it possible to perform more delicate and complex procedures such as pancreaticoduodenectomy. With the introduction of breakthrough chemotherapy regimens, neoadjuvant therapy for pancreatic cancer has been advocated in some centers.
Dr. Yi-Ming Shyr
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- pancreatic cancer
- pancreaticoduodenectomy
- minimally invasive surgery
- robotic surgery
- diagnosis
- treatment
- neoadjuvant therapy
- adjuvant therapy
